Table 2 summarizes womens’ responses regarding acceptability of potential microbicides (n = 506). The groups were similar in their experience with the use of a personal/vaginal lubricant. When asked if they would use a microbicide with the characteristics of KY jelly, 324 (64%) women answered “yes,” 75 (15%) answered “maybe,” and 107 (21%) answered “no.” There was no difference in acculturation among the women who answered yes or maybe (data not shown), and thus we considered these 399 women to be potential microbicide users.
Table 3 presents the likelihood of sexual risk taking behaviors, given an effective microbicide, among potential microbicide users (n = 399). Of note, there was no difference in risk taking behaviors among the 324 women who answered they would use microbicides versus the 75 women who answered they might use microbicides (data not shown). There was a trend, which was significant in 3 risk behaviors (1-night stands, multiple sexual partners, and unprotected sex), of the AH women reporting that they would potentially be more likely to engage in risk taking behaviors, given an effective microbicide. Of note, of the 8 sexual risk behaviors asked, the major behavioral change noted was nonuse of condoms. The reliability coefficient (α) of our 8 question sexual risk-taking scale was 0.71. Because the condom question had a large effect, we recalculated the reliability coefficient without it: the resulting coefficient was 0.76.
The overall mean sexual risk taking score (including the condom question) was significantly higher among AHs (1.14 ± 1.46) than LAHs (0.67 ± 1.11) and AAs (0.51 ± 0.81) (P <0.001). The significant differences in the means persisted among the 3 cohorts even when the condom question was removed (data not shown).
Of note, at baseline, AHs were significantly younger and less likely to report weekly church attendance. In addition, AAs had significantly higher educational attainment and were less likely to report being unemployed and not in school. Because these 4 variables may be associated with sexual risk taking, we controlled for these potential confounders in the logistic regression analyses outlined in Table 3.
We examined baseline levels of condom use, 1-night stands, multiple sexual partners, and having intercourse within 7 days of meeting a male partner (which we correlated with “having sex before you got to know a man”) among the 399 women who reported that they would use future microbicides. We contrasted these self-reported baseline behaviors with the likelihood of behavioral change reported by the women, given the advent of effective microbicides. We were particularly interested in women who reported “SAFE” baseline behaviors (using condoms, 1 sexual partner etc.) who might be negatively impacted by microbicide availability. We found that potential risk disinhibition and condom migration among these participants was most likely to occur among AHs; these data are provided in Table 4.
We have described microbicide acceptability and sexual risk-taking behaviors among a large cohort of MA and AA women who, at baseline, had a laboratory-verified STI. This indicates that all of these women, or their partners, had engaged in high risk sexual behavior.18 Thus, these women may benefit most from microbicide use and their opinions regarding microbicides, use patterns, and behaviors are important to microbicide research, development, marketing, and education.
We found high theoretical acceptability of potential vaginal microbicides (77%–83%) among these women, consistent with other acceptability trials in Thailand, Africa, Puerto Rico, India, and the United States.19–24 Our data agree with previously published findings that acceptability of microbicides is similar among AA and MA women.21 Our patients reported that they would use microbicides with casual or steady partners and this was not associated with either ethnicity or acculturation.
Concern has been expressed in the literature that if microbicides were available, people would not use condoms, termed “condom migration.”6,9 This phenomenon has been documented after nonoxynol-9 trials.25 Ideally, at risk women would use condoms and microbicides, rather than substituting microbicides for condoms, because we do not yet know the efficacy of potential microbicides. We found that significantly more AHs reported that they would not or probably would not use condoms, given an effective microbicide. In addition, AHs who used condoms at baseline were more likely to report a change to nonuse, if microbicides were effective. These findings suggest that STI prevention messages, specifically condom use, need continued emphasis even after the advent of microbicides, particularly in similar populations of AH women.8
There is concern that the real or perceived efficacy of microbicides will increase people’s sexual risk taking behaviors.6,8 Many microbicide products are similar to personal vaginal lubricants, and may be marketed not only to protect against STIs, but to enhance sexual pleasure.19,26 Some authors have noted increased frequency of sexual intercourse during microbicide trials, which may be due to the enhanced lubrication offered by microbicides, but may also be attributable to increased communication among couples enrolled in research studies.7,26,27
Our cohort was similar at baseline in several risk factors. AAs were more likely to be infected with different STIs than Hispanics and with multiple STIs. However, when questioned about sexual behaviors given an effective microbicide, there was a trend, significant in 3 variables, of potential increased risk taking behaviors among AHs. Among the 8 sexual risk taking behaviors, the largest effect was in nonuse of condoms, with relatively few women reporting other risky sexual behaviors, like having sex with a human who shoots up or who has symptoms of a STI. A strength of our data were that the behavior trends were significant even after controlling for age, a well-known risk for STI acquisition.
A major emphasis in microbicide research is to determine the acceptability of the products in at-risk populations. A correlate of acceptability research is to determine how at risk populations might behave, given the advent of a new prevention product. We have previously found that the SAFE behavioral intervention reduces recurrent STIs in MA and AA women.15,28,29 Because the efficacy of potential microbicides is not fully defined, previously tested STI prevention messages, such as the SAFE intervention, should continue as we educate women and men about microbicide use.
Much has been written about the “Epidemiologic Paradox” or “Hispanic Paradox” of better health outcomes to foreign-born women, who are often from more disadvantaged socio-economic groups.30–33 The “Hispanic Paradox” has been attributed to some variables that are not easily defined such as respect for authority, elders and family, a sense of community, and importance of cultural heritage and religion.30 In this study, we found that church attendance differed among the 3 cohorts and thus controlled for this variable in measuring sexual risk taking.
Our study is unique because the majority of our subjects were born in the United States and all entered our clinic with the same risk factor, a laboratory-verified STI. However, even among this high-risk cohort, we have identified a subset of women, AH women, who may need additional counseling on STI prevention with the advent of effective microbicides.
A woman’s risk for HIV and other STIs is often related to behaviors beyond her direct control, particularly her partner’s risky practices.34,35 Because cooperation from the sexual partner is not necessarily required, microbicides will potentially add another option for HIV and STI prevention, particularly in vulnerable women who cannot negotiate condom use or monogamy.34–36 Nevertheless, many studies found that perceived partner acceptability of microbicides and the type of partnership were important considerations for womens’ use patterns.19,21,22,24,27,28,35 For example, it has been described that women would be more likely to use the product covertly with casual or paying sexual partners.19 We found that LAHs were significantly more likely to want to use microbicides without their sexual partner’s knowledge and were significantly more likely to report that concealed use was an important attribute of potential microbicides. Ethnic differences regarding preferences for covert use has been previously reported, with Latina and white women more likely to desire covert use, as compared to AA women.19
Previous studies reported that women thought covert use would be difficult or feared consequences should their partner(s) discover they were using a microbicide secretly.19,24,35 Because violence is a concern with concealed use of a microbicide, we determined the baseline level of sexual or physical abuse in our population. The rate of current or past abuse was high (10%–14%) and there was a trend toward increased rates in LAHs. We found that women were willing to pay similar prices for microbicides and this cost estimate did not differ among ethnic or acculturation groups. The price of microbicides will also be in the decision to disclose use of a product, particularly in women whose partner(s) control their finances.35 Our data suggest that microbicide marketing to LAHs may want to emphasize the ability of the female to control this STI prevention product.
Another major concern of potential microbicide users is the effect of microbicide use on future fertility.28 Our groups were similar in their plans to have more children, their concern for future fertility, and their current pregnancy status. However, AHs were significantly more interested in a product that prevented STIs, but not pregnancy. This unique finding may explain why the AH women in this cohort reported that they were more likely to not use condoms, given effective microbicides. When asked about a combination microbicide/contraceptive, our cohorts expressed similar interest, and levels consistent with results from other studies.19,36–38 Previous investigators found that most (82%) women planned to use adjunct contraception (for e.g., condoms) with an anti-HIV microbicide and 50% planned to use condoms in addition to an anti-HIV, contraceptive microbicide.36 Our data emphasizes how health educators and clinicians will need to understand a woman’s motivations to prevent STIs and or pregnancy given effective microbicides.
The main limitation of this study is that we measured reported potential behaviors, rather than validated behaviors occurring in the context of a microbicide trial. However, participants responses showed a consistent theme, significant in several questions, regarding possible risk disinhibition which might occur if microbicides were available. Also, our risk-taking questions were based on an assumption that microbicides would be 90% effective. It is unknown how effective microbicides will be, and it is likely that the risk taking behaviors would be different if we assumed lower microbicide efficacy.
There has been an association between use of vaginally inserted contraceptive products and microbicide acceptability.23 However, current or past use of the contraceptive ring, female condom, or spermicidal jells and foams was so infrequent in our cohort that we could not correlate use of these vaginal contraceptive products with microbicide use patterns or acceptability. Finally, although we showed the patients KY jelly, we did not ask about acceptability of candidate microbicides of suppository or ring form.
Our data shows that among at-risk minority women infected with an STI, acceptability of potential microbicides was high. LAH women were significantly more likely to desire a microbicide, which they could use covertly. Although our cohorts were similar at baseline in several risk factors for STI acquisition, AH women showed consistent increased likelihood of potential risk disinhibition given the possibility of effective microbicides. These potential use patterns should be considered in the development and marketing of microbicides. This data can also be used by public health educators and clinicians, dealing with similar populations, to effectively counsel women on effective STI prevention practices, given the advent of new STI prevention products.
1. Alliance for Microbicide Development. Mapping the Microbicide Effort. Available at: http://www.microbicide.org
. Accessed July 2008.
3. Hoffman S, Cooper D, Ramjee G, et al. Microbicide acceptability: Insights for future directions from providers and policy makers. AIDS Educ Prev 2008; 20:188–202.
4. Centers for Disease Control and Prevention. 2006 Sexually transmitted diseases treatment guidelines. MMWR 2006; 55:589–592.
6. Hogben M, Liddon N. Disinhibition and risk compensation: Scope, definitions, and perspective. Sex Transm Dis 2008; 35:1009–1010.
7. Guest G, Johnson L, Burke H, et al. Changes in sexual behavior during a safety and feasibility trial of a microbicide/diaphragm combination: An integrated qualitative and quantitative analysis. AIDS Educ Prev 2007; 19:310–320.
8. Cassell MM, Halperin DT, Shelton JD, et al. Risk compensation: The Achilles’ heel of innovations in HIV prevention? BMJ 2006; 332:605–607.
9. Foss AM, Vickerman PT, Heise L, et al. Shifts in condom use following microbicide introduction: Should we be concerned? AIDS 2003; 17:1227–1230.
10. Chen FH. The impact of microbicides and changes in condom usage on HIV prevalence in men and women. AIDS 2006; 20:1551–1553.
11. Marin G, Sabogal F, Marin BV, et al. Development of a short acculturation scale for Hispanics. Hisp J Behav Sci 1987; 9:183–205.
12. Marin BV, Gomez CA, Tschann JM. Condom use among Hispanic men with secondary female sexual partners. Public Health Rep 1993; 108:742–750.
13. Marin BV, Gomez CA, Hearst N. Multiple heterosexual partners and condom use among Hispanics and non-Hispanic whites. Fam Plann Perspect 1993; 25:170–174.
14. Centers for Disease Control and Prevention. Trends in reportable sexually transmitted diseases in the United States, 2005: National surveillance data for Chlamydia, gonorrhea, and syphilis. Atlanta, GA: US Department of Health and Human Services, CDC, 2006.
15. Shain RN, Piper JM, Newton ER, et al. A randomized, controlled trial of a behavioral intervention to prevent sexually transmitted disease among minority women. N Engl J Med 1999; 340:93–100.
16. Catania JA, Kegeles SM, Coates TJ. Towards an understanding of risk behavior: An AIDS risk reduction model (ARRM). Health Educ Q 1990; 17:53–72.
17. Ramos R, Shain RN, Johnson L. “Men I mess with don’t have anything to do with AIDS”: Using ethno-theory to understand sexual risk perception. Sociol Q 1995; 36:483–504.
18. Centers for Disease Control and Prevention. 2006 Sexually transmitted diseases treatment guidelines. MMWR 2006; 55:1–94.
19. Hammett TM, Norton GD, Mason TH, et al. Drug-involved women as potential users of vaginal microbicides for HIV and STD prevention: A three-city survey. J Womens Health Gend Based Med 2000; 9:1071–1080.
20. Short MB, Succop PA, Ugueto AM, et al. Predictors of using a microbicide-like product among adolescent girls. J Adolesc Health 2007; 41:357–362.
21. Morrow KM, Fava JL, Rosen RK, et al. Willingness to use microbicides varies by race/ethnicity, experience with prevention products and partner type. Health Psychol 2007; 26:777–786.
22. Jones DL, Weiss SM, Chitalu N, et al. Acceptability of microbicidal surrogates among Zambian women. Sex Transm Dis 2008; 35:147–153.
23. Weeks MR, Mosack KE, Abbott M, et al. Microbicide acceptability among high-risk urban US women: Experiences and perceptions of sexually transmitted HIV prevention. Sex Transm Dis 2004; 31:682–690.
24. Bently MA, Fullem AM, Tolley EE, et al. Acceptability of a microbicide among women and their partners in a 4-country phase 1 trial. Am J Pub Health 2004; 94:1159–1164.
25. Wong EL, Roddy RE, Tucker H, et al. Use of male condoms during and after randomized, controlled trial participation in Cameroon. Sex Transm Dis 2005; 32:300–307.
26. Kilmarx PH, Blanchard K, Chaikummao S, et al. A randomized, placebo-controlled trial to assess the safety and acceptability of use of Carraguard vaginal gel by heterosexual couples in Thailand. Sex Transm Dis 2008; 35:226–232.
27. Whitehead SJ, Kilmarx PH, Blanchard K, et al. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS 2006; 20:2141–2148.
28. Shain RN, Perdue ST, Piper JM, et al. Behaviors changed by intervention are associated with reduced STD recurrence: The importance of context in measurement. Sex Transm Dis 2002; 29:520–529.
29. Thurman AR, Holden AEC, Shain RN, et al. Preventing recurrent sexually transmitted diseases in minority adolescents: A randomized controlled trial. Obstet Gynecol 2008; 111:1417–1425.
30. Markides KS, Coreil J. The health of Hispanics in the southwestern United States: An epidemiologic paradox. Public Health Rep 1986; 101:253–265.
31. Gould JB, Madan A, Qin C, et al. Perinatal outcomes in two dissimilar immigrant populations in the United States: A dual epidemiologic paradox. Pediatrics 2003; 111:e676–e682.
32. Reed MM, Westfall JM, Bublitz C, et al. Birth outcomes in Colorado’s undocumented immigrant population. BMC Public Health 2005; 5:100–106.
33. David RJ, Collins JW. Differing birth weight among infants of US-born blacks, African-born blacks, and US-born whites. N Engl J Med 1997; 337:1209–1214.
34. Woodsong C, Allenman P. Sexual pleasure, gender power, and microbicide acceptability in Zimbabwe and Malawi. AIDS Educ Prev 2008; 20:171–187.
35. Woodsong C. Covert use of topical microbicides: Implications for acceptability and use. Int Fam Plan Perspect 2004; 30:94–98.
36. Ojikutu BO, Stone VE. Women, inequality, and the burden of HIV. N Engl J Med 2005; 352:649–652.
37. Morrow KM, Fava JL, Rosen RK, et al. Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties. J AIDS 2007; 45:93–101.
© Copyright 2009 American Sexually Transmitted Diseases Association
38. Olsen ML, Cwiak CA, Koudella C, et al. Desired qualities and hypothetical contextual use of vaginal microbicides in a diverse sample of US women. Contraception 2007; 76:314–318.